Kakhnovskiĭ I M, Sivkov S I, Markova Z S, Ivanova I L, Sivkov A S
Kafedra vnutrennikh bolezneĭ No. 1 2-go lechebnogo fakul'teta MMA im. I.M. Sechenova.
Klin Med (Mosk). 1997;75(12):48-52.
The study included 30 patients with COB coursing from 5 to 15 years, free of chronic cor pulmonale symptoms. All the patients had moderate obstructive impairment of pulmonary ventilation with hemodynamic disorders and defects in myocardial contractility indicating the presence of transitory pulmonary hypertension (PH). Patients of the control group received conventional therapy. It was combined with isoptin-retard (240 mg/day) in the study group. The treatment produced a positive effect in all the patients, but those of the study group exhibited more pronounced decrease in pulmonary artery pressure, achieved better hemodynamics and myocardial contractility. Isoptin-retard in daily dose 240 mg is recommended in COB patients to prevent onset of chronic cor pulmonale.
该研究纳入了30例病程为5至15年、无慢性肺源性心脏病症状的慢性阻塞性支气管炎(COB)患者。所有患者均有中度肺通气阻塞性损害,伴有血流动力学紊乱和心肌收缩力缺陷,提示存在短暂性肺动脉高压(PH)。对照组患者接受常规治疗。研究组在常规治疗基础上加用缓释异搏定(240毫克/天)。治疗对所有患者均产生了积极效果,但研究组患者的肺动脉压下降更为明显,血流动力学和心肌收缩力改善更佳。建议对慢性阻塞性支气管炎患者每日服用240毫克缓释异搏定,以预防慢性肺源性心脏病的发生。